An isolated monoclonal antibody or antigen-binding fragment thereof characterized by specific binding to HcTnT-N69 (69-amino acid fragment of N-terminus of human cardiac troponin T), comprising:
- 1) a VH region comprising amino acid sequence SEQ ID NO:2, or a variant thereof having 90% or greater identity;
- and a VL region comprising amino acid sequence SEQ ID NO:3 or SEQ ID NO:6 or a variant of either thereof having 90% or greater identity;
- 2) a VH region comprising amino acid sequence SEQ ID NO:8, or a variant thereof having 90% or greater identity;
- and a VL region comprising amino acid sequence SEQ ID NO:9 or a variant thereof having 90% or greater identity;
- 3) a VH region comprising amino acid sequence SEQ ID NO:12, or a variant thereof having 90% or greater identity;
- and a VL region comprising amino acid sequence SEQ ID NO:13, SEQ ID NO:
- 16, SEQ ID NO:
- 18, SEQ ID NO:20, or a variant of any thereof having 90% or grater identity;
- 4) a VH region comprising amino acid sequence SEQ ID NO:2, or a conservative substitution variant thereof;
- and a VL region comprising amino acid sequence SEQ ID NO:3 or SEQ ID NO:6 or a conservative substitution variant of either thereof;
- 5) a VH region comprising amino acid sequence SEQ ID NO:8, or a conservative substitution variant thereof;
- and a VL region comprising amino acid sequence SEQ ID NO:9 or a conservative substitution variant thereof;
- 6) a VH region comprising amino acid sequence SEQ ID NO:12, or a conservative substitution variant thereof;
- and a VL region comprising amino acid sequence SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, or a conservative substitution variant of any thereof, wherein the conservative substitution variant of any of SEQ ID NOs. 2, 3, 6, 8, 9, 12, 13, 16, 18, and 20 comprises at least on substitution of an acidic, basic, aliphatic, or aromatic amino acid with a different acidic, basic, aliphatic, or aromatic amino acid, respectively;
- 7) a VH region comprising complementarity determining region (CDR) 1 consisting of amino acid (aa) 18 to aa 28 of SEQ ID NO:2, CDR 2 consisting of aa 43 to aa 52 of SEQ ID NO:2 and CDR 3 consisting of aa 92 to aa %9 of SEQ ID NO:2;
- and a VL region comprising CDR 1 consisting of aa 21 to aa 31 of SEQ ID NO:3, CDR 2 consisting of aa 43 to aa 52 of SEQ ID NO:3 and CDR 3 consisting of aa 86 to aa 93 of SEQ ID NO:3;
- or CDR 1 consisting of aa 21 to aa 31 of SEQ ID NO:6, CDR 2 consisting of aa 43 to aa 52 of SEQ ID NO:6 and CDR 3 consisting of aa 86 to a 93 of SEQ ID NO:6;
- 8) A VH region comprising CDR 1 consisting of aa 18 to aa 28 of SEQ ID NO:8, CDR 2 consisting of aa 43 to aa 52 of SEQ ID NO:8 and CDR 3 consisting of aa 90 to aa 96 of SEQ ID NO:8;
- and a VL region comprising CDR 1 consisting of aa 21 to aa 31 of SEQ ID NO:9, CDR 2 consisting of aa 43 to aa 52 of SEQ ID NO:9 and CDR 3 consisting of aa 86 to aa 93 of SEQ ID NO:9;
- 9) a VH region comprising CDR 1 consisting of aa 18 to aa 28 of SEQ ID NO:12, CDR 2 consisting of aa 41 to aa 59 of SEQ ID NO:2 an DR 3 consisting of aa 92 to aa 102 of SEQ ID NO:12;
- and a VL region comprising CDR 1 consisting of aa 21 to aa 31 of SEQ ID NO:13, CDR 2 consisting of aa 43 to aa 52 of SEQ ID NO:13 and CDR 3 consisting of aa 86 to a 93 of SEQ ID NO:13;
- or CDR 1 consisting of aa 21 to aa 31 of SEQ ID NO:16, CDR 2 consisting aa 43 to aa 52 of SEQ ID NO:16 and CDR 3 consisting aa 86 to aa 3 of SEQ ID NO:16;
- or CDR 1 consisting of aa 21 to aa 3 of SEQ ID NO:18, CDR 2 consisting of aa 43 to aa 52 of SEQ ID NO:18 and CDR 3 consisting of aa 86 to aa 93 of SEQ ID NO:18;
- or CDR 1 consisting of aa 21 to aa 31 of SEQ ID NO:20, CDR 2 consisting of aa 43 to aa 52 of SEQ ID NO 20 and CDR 3 consisting of aa 86 to aa 93 of SEQ ID NO:20.